About

Cancer demands diagnostic and therapeutic measures with proven quality, safety and efficacy and surgery, chemo-, radio- and hormone therapy have emerged as the gold standard in the treatment of carcinomas. Complementary medicine is currently widely debated by the oncological community, because of a lack of the required scientific proof of safety and effectiveness. However, complementary approaches in oncology can be recommended as additional to orthodox cancer therapies to optimise these therapies. A great body of data emerging from scientifically sound clinical trials prove that defined complementary procedures are beneficial for the patients. More than 80% of the cancer patients apply complementary medicine to their protocols. Over the last 20 years, there has been an increasingly number of research papers on complementary oncology. Many herbs and/or isolates from herbs have been tested both in vivo and in vitro with often good results. ICOP has a number of examples of this research, many largely unknown but without doubt of benefit to the cancer patient. Note: This information is designed for professionally trained complementary practitioners and is not a recommendation for treatment.

ICOP supports the use of evidence-based practice, which aims to apply the best available evidence gained from the scientific method to clinical decision making.

Wong, Sagar and Sagar (2001) suggest that recent evidence shows many traditional Chinese medical therapies are effective for the supportive care of cancer patients. Their review of some of the published literature (indexed in Medline) and their own practical experience provide various levels of evidence which support further research into a developing model of integrative care. The holistic approach of Traditional Chinese Medicine (TCM) may be integrated into conventional Western Medicine to supplement deficiencies in the current biomedical model.
In another study by Donald Yance and Steven Sagar (2006), it was found that an integrative approach for managing a patient with cancer should target the multiple biochemical and physiological pathways that support tumor development while minimizing normal tissue toxicity. They found the following herbs, which are traditionally used for anticancer treatment and are antiangiogenic through multiple interdependent processes, which include effects on gene expression, signal processing, and enzyme activities.
Artemisia annua (Chinese wormwood), Viscum album (European mistletoe), Curcuma longa (turmeric), Scutellaria baicalensis (Chinese skullcap), resveratrol and proanthocyanidin (grape seed extract), Magnolia officinalis (Chinese magnolia tree), Camellia sinensis (green tea), Ginkgo biloba , quercetin, Poria cocos , Zingiber officinale (ginger), Panax ginseng , Rabdosia rubescens (rabdosia), and Chinese destagnation herbs.
Wong R, Sagar CM & Sagar SM. Integration of Chinese medicine into supportive cancer care: A modern role for an ancient tradition. Cancer Treatment Reviews. Volume 27, Issue 4, August 2001, Pages 235-246
Yance DR & Sagar SM. Targeting Angiogenesis With Integrative Cancer Therapies. Integr Cancer Ther March 2006 vol. 5 no. 1 9-29. doi: 10.1177/1534735405285562